Buy, Sell, or Hold: Vical
When considering any stock for your portfolio, don't be swayed by just the positives. Examine its pros and cons, and decide whether it's possible that the upside outweighs its risks. Let's take a look at Vical today, and see why you might want to buy, sell, or hold it.
Founded in 1987 and based in San Diego, Calif., Vical is a biotechnology concern with a market capitalization near $280 million, meaning it's a relatively small company. It's focused on "vaccines and gene therapies, and delivering on the promise of novel preventive and therapeutic alternatives for serious and life-threatening diseases."
Vical's stock has shed about 6% over the past year, averaged a 30% annual gain over the past two years, and averaged 3% over the past decade.
One reason to consider buying Vical is its business. With the world's population growing, getting older, and living longer, demand for health care products and services is likely to remain in demand. Vical's focus on infectious diseases and cancer therapies, among other things, is positioned to serve it well.
Another reason to like Vical is its small size. It's true that small-cap companies can be more volatile than their blue-chip counterparts, but they can also grow more briskly, and have more room to grow -- assuming they execute smart strategies well. The company recently reported quarterly earnings with a smaller-than-expected loss.
One factor that can help a small biotech company become a bigger one is actually having products approved by regulatory authorities and on the market. Vical has ONCEPT approved in the U.S. and Apex-IHN approved in Canada. They treat, respectively, dogs with oral melanoma and farm-raised salmon vulnerable to an infectious necrosis virus. (Don't laugh -- pet owners take their companions' health seriously, and salmon is a valuable food "crop.")
Another critical factor for biotech companies is their pipeline. Vical has a handful of formulas in trials, several of which are nearing the end of the process, in phase 3 proceedings. These include Transvax, protecting against infection following stem-cell transplants; Allovectin, treating metastatic melanoma; and Collategene, aiming to increase the growth of blood vessels. Allovectin is not yet approved, but if it wins approval, Vical is likely to pursue approvals for other indications as well. And the melanoma market is a big one, with hundreds of millions of dollars in revenue possible.
While small caps do have lots of room to grow, many of them don't do so. Vical Pharmaceuticals' stock price, recently around $3.30 per share, is firmly in penny-stock territory, where extra-risky companies abound and many fortunes have been lost. It's not a guaranteed sign of disaster, but it's a red flag to keep in mind.
Another reason to stay away from Vical -- and other biotech companies -- is that most of us know very little about biotechnology and related fields. Thus, it can be especially hard for us to discern which companies are best poised for success, and what the risks are for each. For example, Vical's Allovectin is expected to be a costly drug, like Dendreon's prostate cancer drug Provenge. Costliness adds complexity to an investor's calculations, as it's less clear whether consumers and insurers will pony up for the treatment. Dendreon has risen lately, partly on expectations of good news from Europe, but it also has its detractors.
It can make a lot of sense for many investors to just steer clear of the whole field, or to invest in a bunch of biotech companies at once, via an ETF. The iShares Nasdaq Biotechnology ETF , for example, can instantly have you invested in more than 100 companies, such as Ariad Pharmaceuticals , which has received FDA approval for its leukemia drug ponatinib, now known as Iclusig. Its bone-tumor drug ridaforolimus was rejected in Europe, but it might still prove effective against other cancers. The company has been spending heavily on research and development, and it needs some more success from its pipeline, as well as a successful launch of Iclusig. Ariad reports its latest earnings today, with investors eager to see how optimistic management is about 2013 revenue.
Vical's financial statements offer a few concerns. Its revenue growth has been bumpy, and its net earnings have been net losses for quite a few years. On the plus side, though, it has plenty of cash and little debt. Its free cash flow is negative, reflecting a cash burn of less than $20 million annually, but its cash of $86 million in its last quarter should last it several years.
Don't like volatility? Perhaps steer clear of Vical. Check out its annual returns from 2008 to 2012: down 67%, up 133%, down 39%, up 118%, down 34%. So far this year, it's up about 23%.
Dilution is another concern, as Vical's share count has more than doubled from about 40 million in 2008 to around 86 million million recently. The more shares there are, the smaller each one's stake is in the company. Dilution is generally not desirable, but it reflects a company generating more funds, which might be deployed to help the company grow faster. So it's not necessarily a deal-breaker.
Finally, Vical's valuation isn't the most attractive, per a few measures. Its P/E ratio is negative, as its bottom line is in the red. Its price-to-sales ratio is a hefty 16, well above its five-year average of 11.6 and the industry average of 6.5.
Given the reasons to buy or sell Vical, it's not unreasonable to decide to just hold off on it. You might want to wait for a series of quarters featuring net gains instead of losses, or for one or more drugs in Vical's pipeline to gain regulatory approval, paving the way for revenue and profits.
You might also check out some other interesting biotech companies, to see if they seem like better bargains than Vical. Perhaps take a look at Dynavax , which has a vaccine against hepatitis B nearing a regulatory decision. It's a promising market, and the company is looking into getting the drug approved for other treatments. It, too, is a penny stock, though, with some red flags.
I'm holding off on Vical for now. Everyone's investment calculations are different, though. Do your own digging and see what you think. The company may perform spectacularly in the coming years, but remember that there are plenty of compelling stocks out there.
Resurgence, or dead cat bounce?
Shares of Dendreon have surged in recent months, with the stock gaining new life from the depths of late 2012. Has the company really solved its underlying problems, or are investors setting themselves up for more disappointment? Our new premium research report on Dendreon answers these questions, and many more, while also outlining just how Dendreon intends to regain its former glory. Claim your copy, and a year of free analyst updates, by clicking here now.
The article Buy, Sell, or Hold: Vical originally appeared on Fool.com.Longtime Fool contributor Selena Maranjian, whom you can follow on Twitter, has no position in any stocks mentioned. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.